Qyuns Therapeutics Co., Ltd.
江蘇荃信生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2509)

UNAUDITED INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

The Board is pleased to announce the unaudited condensed consolidated results of the Group for the six months ended June 30, 2025, together with the unaudited comparative figures for the six months ended June 30, 2024. The unaudited consolidated financial statements of the Group for the Reporting Period have been reviewed by the Audit Committee and the auditor of the Company.

FINANCIAL HIGHLIGHTS

Operating Results	**For the six months ended June 30,**	
	2025	2024
	RMB'000	*RMB'000*
	(Unaudited)	(Unaudited)
Revenue	**206,486**	44,919
Cost of sales	**(28,868)**	(7,163)
Gross Profit	**177,618**	37,756
Other net income	**7,162**	7,402
Research and development expenses	**(151,394)**	(145,226)
Loss for the period	**(30,933)**	(183,139)
Loss per share – Basic and diluted *(in RMB)*	**(0.13)**	(0.79)
Adjusted loss for the period (as illustrated under "**Non-IFRS Measures**")	**(5,221)**	(132,501)

Financial Position	**As of**	
	June 30, 2025	December 31, 2024
	RMB'000	*RMB'000*
	(Unaudited)	(Audited)
Cash and cash equivalents, time deposits, and financial assets at fair value through profit or loss (FVPL)	**558,897**	556,127
Total non-current assets	**453,091**	367,152
Total current assets	**679,061**	616,725
Total non-current liabilities	**465,281**	332,666
Total current liabilities	**451,042**	430,161
Net current assets	**228,019**	186,564
Total equity	**215,829**	221,050

Revenue

The Group's revenue amounted to RMB206.49 million for the six months ended June 30, 2025, mainly including: (i) revenue from licensing agreement, including upfront fee and non-cash consideration of approximately 24.88% equity interest in Caldera Therapeutics, Inc. in relation to overseas licensing of QX030N, as well as the milestone fee for the first patient enrollment in Phase III of QX004N, totalling RMB180.77 million; and (ii) revenue from CDMO services and provision of R&D services for the QX004N and QX008N projects of approximately RMB22.00 million.

Cost of Sales

Our Group's cost of sales amounted to RMB28.87 million for the six months ended June 30, 2025, which mainly consists of (i) relevant costs incurred from CDMO services; (ii) relevant costs incurred from R&D services provided for QX004N and from overseas licensing of QX030N; and (iii) provisions for write-down of inventories and other contract costs.

Research and Development Expenses

Our R&D expenses increased by 4.25% from RMB145.23 million for the six months ended June 30, 2024 to RMB151.39 million for the six months ended June 30, 2025, including decrease of RMB5.87 million in amortization of equity-settled share-based payment and increase of RMB12.04 million in R&D expenses primarily attributable to the increase in clinical trial costs resulting from the advancement of clinical trials of the Company.

Non-IFRSs Measures:[(1)]

	2025	2024	Changes	Period-on period changes
	RMB'000	*RMB'000*	*RMB'000*	*%*
Loss for the period	**(30,933)**	(183,139)	152,206	(83%)
Add:				
Equity-settled share-based payment expenses	**25,712**	50,638	(24,926)	(49%)
Adjusted loss for the period	**(5,221)**	(132,501)	127,280	(96%)

(1) Adjusted loss for the period represents the loss for the period excluding the effect of certain non-cash items, namely the share-based compensation expenses. The term adjusted loss for the period is not defined under IFRSs. The use of this non-IFRSs measure has limitations as an analytical tool, and you should not consider it in isolation from, or as a substitute for analysis of, our results of operations or financial condition as reported under IFRSs. Our presentation of this adjusted figure may not be comparable to similarly titled measures presented by other companies. However, we believe that this non-IFRSs measure reflects our core operating results by eliminating potential impacts of items that our management do not consider to be indicative of our core operating performance, and thus, facilitate comparisons of core operating performance from period to period and company to company to the extent applicable.

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

Founded in 2015, we are a biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases, fully covering dermatology, respiratory, gastroenterology and rheumatology. With an integrated strategy encompassing R&D, production and commercial collaboration, we aim to fully unlock the commercial value of our pipeline products, form a progressive R&D and commercialization matrix, and continue to solidify our leading position in the autoimmune field and improve the treatment standards for related diseases through the efficient development of a series of bispecific antibody products.

As of the date of this announcement, we have one commercialized product, namely SAILEXIN, China's first ustekinumab biosimilar. Two core products are progressing smoothly in development. In particular, QX005N (anti-IL-4Rα mAb) completed patient enrollment for the Phase III trial in China for prurigo nodularis (PN) in March 2025, and patient enrollment for the Phase III trial in China for atopic dermatitis (AD) is nearing completion, with such trials expected to read out primary endpoint data at the end of this year and early next year, respectively. QX002N (anti-IL-17A mAb) reached the primary endpoint in the Phase III trial in China for ankylosing spondylitis (AS) in February 2025 and is planned for BLA submission within this year. QX004N (anti-IL-23p19 mAb) and QX008N (anti-TSLP mAb) are in Phase III clinical trial for psoriasis (Ps) and Phase II clinical trial for chronic obstructive pulmonary disease (COPD) in China, respectively, with partners accelerating their development. Such tiered product pipeline significantly strengthens our R&D and commercialization foundation, providing greater certainty for the Company's future growth.

Furthermore, leveraging our deep expertise in the autoimmune field, we have efficiently developed a series of long-acting bispecific antibody products to address the shortcomings of existing therapies. With the continuous expansion of potential first-in-class (FIC) and best-in-class (BIC) products in our pipeline, the Company will speed up product iteration and global collaboration to accelerate the implementation of globalization strategy.

We have successfully accomplished strategic collaborations with the following business partners for the development and commercialization of our Core Products and other key products:

- ***QX008N/JKN24011***

  In January 2024, we entered into a technology transfer agreement with Joincare and granted exclusive rights to Joincare to develop, manufacture, and commercialize QX008N in Mainland China, Hong Kong, and Macau.

- ***QX004N/HS-20137***

  In April 2024, we entered into an exclusive out licensing agreement (the "**License-Out Agreement**") with Hansoh (Shanghai) for the research and development, manufacturing, and commercialization of QX004N within Mainland China, Hong Kong, Macau and Taiwan (the "**Authorized Territory**"). Based on the agreement, Hansoh (Shanghai) has paid an upfront payment of RMB75.0 million and is required to make potential payments upon reaching R&D, regulatory and sales-based commercial milestones of up to RMB1,032.0 million, plus tiered royalties on future product sales. QX004N has entered Phase III clinical trial as of the date of the announcement, being the fourth product in the Company's pipeline to be successfully advanced to Phase III stage. As of the date of the announcement, the Company has received payments for reaching Phase III milestone of Ps and other payment of RMB58.0 million in aggregate from Hansoh Pharma according to the License-Out Agreement.

- ***QX005N/HDM3016***

  In July 2024, we entered into a Cooperation Agreement with Zhongmei Huadong, pursuant to which Zhongmei Huadong will co-develop QX005N together with the Company within the Authorized Territory, including clinical and non-clinical studies and registration related work. The collaboration includes 50/50 cost sharing for Phase III clinical trial costs, accelerating late-stage development and enhancing the commercialization potential in the future.

- ***QX030N***

  In April 2025, the Company and Caldera Therapeutics, Inc. ("**Caldera**") have entered into an out-license agreement (the "**License Agreement**"), under which Caldera is granted an exclusive right to develop and commercialize QX030N globally. As of the date of this announcement, the Company has received upfront payment of US$10 million and approximately 24.88% equity interest in Caldera.

BUSINESS REVIEW

AD: atopic dermatitis
AD: 特應性皮炎
AS: ankylosing spondylitis
AS: 強直性脊柱炎
BsAb: bispecific antibody
BsAb: 雙特異性抗體
CD: Crohn's disease
CD: 克羅恩病
COPD: chronic obstructive pulmonary disease
COPD: 慢性阻塞性肺病
CRSwNP: chronic rhinosinusitis with nasal polyps
CRSwNP: 慢性鼻竇炎伴鼻息肉
CSU: chronic spontaneous urticaria
CSU: 慢性自發性蕁麻疹
IL-4Rα : interleukin-4 receptor subunit α
IL-4Rα : 白介素4受體α亞基
IL-12/IL-23p40: interleukin-12/interleukin-23 subunit p40
IL-12/IL-23p40: 白介素12／白介素23 p40亞基
IL-17A: interleukin-17A
IL-17A: 白介素17A
IL-23p19: interleukin-23 subunit p19
IL-23p19: 白介素23p19亞基
PN: prurigo nodularis
PN: 結節性癢疹
Ps: psoriasis
Ps: 銀屑病
TSLP: thymic stromal lymphopoietin
TSLP: 胸腺基質淋巴細胞生成素
c-kit: a type III receptor tyrosine kinase
c-kit: 一種III型受體酪氨酸激酶

Pipeline progress (presented by indications)



Expected progress of certain products



CTN: Clinical Trial Notification
CTN：臨床試驗備案（澳洲）
QX005N: Huadong Medicine R&D code of HDM3016
QX005N：華東醫藥研發代碼為HDM3016
QX004N: Hansoh Pharma R&D code of HS-20137
QX004N：翰森製藥研發代碼為HS-20137
QX008N: Joincare R&D code of JKN24011
QX008N：健康元研發代碼為JKN24011

Cautionary Statement required under Rule 18A.08(3) of the Listing Rules

There is no assurance that we will ultimately develop or market our Core Products successfully. Shareholders and potential investors of our Company are advised to exercise with caution when dealing in the Shares of our Company.

SAILEXIN (QX001S, Ustekinumab Injection)

SAILEXIN (QX001S, Ustekinumab Injection) was approved by the NMPA in October 2024 as China's first approved ustekinumab biosimilar and our Company's first commercialized product. Approved by the FDA in 2009, ustekinumab (Stelara®) was the first biologic treatment to selectively inhibit the IL-23 and IL-12 pathways and is one of the major treatments for Ps worldwide. According to the 2024 annual report of Johnson & Johnson, the global sales of Stelara® in 2024 amounted to US$10.361 billion (approximately RMB75.221 billion).

After we received the approval for moderate-to-severe plaque psoriasis in adults, Zhongmei Huadong, a subsidiary of Huadong Medicine and our commercialization partner for SAILEXIN, made supplemental application for SAILEXIN for use in pediatric plaque psoriasis and for use in Crohn's disease. Please refer to the announcements of our Company dated December 2, 2024 and February 12, 2025 for further information. On March 3, 2025, Zhongmei Huadong received the Notice of Approval of Supplemental Application for Drugs from the NMPA, and the supplemental application for SAILEXIN to add the new indication of pediatric plaque psoriasis has been approved. Please refer to the announcement dated March 3, 2025 for details. We expect SAILEXIN to be an affordable drug for a broad section of Ps patients and as of June 30, 2025, we have shipped over 60,000 units to Zhongmei Huadong.

QX005N/HDM3016

Being one of our Core Products, QX005N is an innovative humanized monoclonal antibody targeting IL-4Rα. Through specific binding with IL-4Rα, QX005N blocks the binding of IL-4Rα with both IL-4 and IL-13, and also inhibits the signaling pathways and biological effects mediated by IL-4 and IL-13, thus exerting therapeutic effects on type 2 inflammatory allergic diseases. As of the date of this announcement, QX005N injection has received seven IND approvals for various indications, including moderate-to-severe AD in adults, AD in adolescents aged 12-17, PN, CRSwNP, CSU, asthma, and COPD.

The result of Phase II clinical trial of QX005N for PN was released through oral presentation at the 29th Annual Meeting of Chinese Society of Dermatology. Based on the data from such trial, the CDE granted QX005N the breakthrough therapy designation (BTD) for the treatment of PN in January 2024, signifying its superior clinical benefits compared to current treatment methods and making it one of the "only two" IL-4Rα mAbs in China with BTD certification. The BTD is designed to expedite the development and regulatory review of innovative drugs demonstrating substantial potential in addressing serious diseases. As of March 19, 2025, we have completed patient enrollment for the Phase III clinical trial of QX005N for PN, which is the first Phase III clinical trial for PN conducted by a Chinese domestic enterprise in China. Please refer to the announcement of our Company dated March 20, 2025 for further information. In addition, as of the date of this announcement, patient enrollment for the Phase III clinical trial of QX005N for treatment of AD is nearing completion.

We completed the Phase II clinical trial of QX005N for CRSwNP in February 2025.

In July 2024, we entered into a Cooperation Agreement with Zhongmei Huadong, pursuant to which Zhongmei Huadong will co-develop QX005N (Huadong Pharmaceutical R&D code: HDM3016) together with the Company within the Authorized Territory, including clinical and non-clinical studies and registration related work. The collaboration includes 50/50 cost sharing for Phase III clinical trial costs, accelerating late-stage development and enhancing the commercialization potential in the future.

QX002N

Being one of our Core Products, QX002N is a high-affinity monoclonal antibody targeting IL-17A, a key player in the pathological mechanism of various autoimmune diseases. IL-17A inhibitors are recommended by prevailing clinical guidelines as second-line standalone treatment (the same designation as TNF inhibitors) for AS patients with high disease activity after receiving first-line traditional treatments. Between the two classes of biologics *(i.e.,* TNF inhibitors and IL-17A inhibitors), IL-17A inhibitors demonstrate significant clinical benefits for both TNF-α inhibitor-naïve patients and those who are intolerant to or unable to achieve adequate disease control with TNF-α inhibitors.

Topline results for the Phase III clinical trials of QX002N for AS announced on February 24, 2025 that the ASAS40 response rate at week 16 in the treatment group receiving 160 mg of QX002N administered every four weeks (Q4W) was 40.4%, which was significantly higher than the 18.9% in the placebo group ($P < 0.0001$) and the 65.2% ASAS20 response rate of QX002N treatment group also significantly trumps the response rate of placebo group ($P < 0.0001$), which was 41.3%. The trial results confirmed that the trial successfully met both its primary endpoint and key secondary endpoints. Please refer to the announcement of our Company dated February 24, 2025 for further information.

QX004N/HS-20137

QX004N (Hansoh Pharma R&D code: HS-20137) is an IL-23p19 inhibitor for the treatment of Ps and CD. IL-23p19 has emerged as a key target associated with superior efficacy for Ps patients with more severe symptoms or inadequate response to existing treatments.

In December 2024, Phase I clinical data for QX004N was published in JAMA Dermatology, a top-tier journal in dermatology. In March 2025, Phase II clinical data for QX004N was disclosed by our partner Hansoh Pharma in a breakthrough oral presentation at the American Academy of Dermatology (AAD) Annual Meeting. The Phase II study demonstrated robust efficacy and favorable safety of QX004N in patients with moderate-to-severe plaque psoriasis over a 28-week treatment period. After 16 weeks of treatment, 76.9% of subjects achieved ≥90% improvement in Psoriasis Area and Severity Index (PASI) scores from baseline, with this proportion rising to 89.7% at 24 weeks.

In April 2024, we entered into the License-Out Agreement with Hansoh (Shanghai) for the research and development, manufacturing, and commercialization of QX004N within the Authorized Territory. The Company retains all its rights to QX004N outside the Authorized Territory. Under the terms of the License-Out Agreement, Hansoh (Shanghai) has paid an upfront payment of RMB75.0 million and is required to make potential payments upon reaching R&D, regulatory and sales-based commercial milestones of up to RMB1,032.0 million, plus tiered royalties on future product sales. QX004N recently has entered Phase III clinical trial, being the fourth product in the Company's pipeline to be successfully advanced to Phase III stage. Recently, the Company has received payments for reaching Phase III milestone of Ps and other payment of RMB58.0 million in aggregate from Hansoh Pharma according to the License-Out Agreement.

QX008N/JKN24011

QX008N (Joincare R&D code: JKN24011) is a humanized IgG1 mAb targeting TSLP, designed for the treatment of moderate-to-severe asthma and moderate-to-severe COPD. TSLP-targeting therapy (represented by Tezspire® (tezepelumab)) is currently the only approved biologic drug for all phenotypes of asthma in the world. Whether based on baseline eosinophil counts or allergic status (without the need for pre-testing specific biomarkers such as blood eosinophil counts or IgE levels), it significantly reduces the risk of acute exacerbations and delays disease progression in these patients.

In January 2024, we entered into a technology transfer agreement with Joincare to grant Joincare an exclusive license to develop, manufacture and commercialize QX008N in Mainland China, Hong Kong and Macau. Going forward, Joincare will be responsible for proceeding with the subsequent clinical trials and the BLA submission of QX008N and it will be the MAH of QX008N in the aforementioned area, once approved. We retain the exclusive rights to develop, manufacture and commercialize QX008N outside Mainland China, Hong Kong and Macau. As of the date of this announcement, Joincare is conducting Phase ll clinical trial of QX008N for COPD in China, and has completed patient enrollment for the trial.

QX013N

QX013N is a humanized IgG1 mAb targeting c-kit (a type III receptor tyrosine kinase) and indicated for CSU. C-kit is a master regulator of mast cells, which are the primary effector cells in CSU. QX013N specifically binds to c-kit to inhibit the differentiation, maturation, survival, proliferation and degranulation of mast cells, resulting in the reduction and depletion of mast cells for treatment of mast cell-driven diseases such as CSU.

QX013N is the first biologic drug candidate targeting c-kit in China. The IND approval of QX013N in CSU indicates that the Company has established a comprehensive presence in the four major dermatological indications (psoriasis, atopic dermatitis, prurigo nodularis and chronic spontaneous urticaria), further consolidating its competitive advantages in dermatology. As of the date of this announcement, we have completed the Phase Ia clinical trial.

Bispecific Antibody Products

We have developed a series of long-acting bispecific antibodies for autoimmune diseases, aiming to enhance clinical efficacy across multiple indications and extend dosing intervals to improve medication convenience:

- QX027N, targeting respiratory and dermatological indications, planned for IND submissions in China and the U.S. in Q3 2025

- QX030N, planned for CTN submission in Australia in Q4 2025

- QX031N, targeting respiratory indications, planned for IND submissions in China and the U.S. in Q4 2025

- QX035N, targeting respiratory and dermatological indications, planned for IND submissions in China and the U.S. in Q4 2026

Furthermore, leveraging our extensive library of monoclonal antibody molecules for autoimmune targets and scientifically grounded synergy assessments, we are continuously evaluating the therapeutic and BD cooperation potential of a series of bispecific antibody molecules, and will prioritize and advance the most promising ones to IND filing and clinical research stages.

Research and Development

Research and development ("**R&D**") is the cornerstone of our sustained success. Currently, the Company has achieved significant R&D milestones: one monoclonal antibody drug has been approved for marketing, three innovative monoclonal antibody drugs have entered Phase III clinical trials, and one innovative bispecific antibody drug has been licensed overseas, fully validating our R&D capabilities and the commercial value of our products. Continuously enhancing R&D capabilities and consistently delivering innovative products with potential differentiation advantages are critical to maintaining our industry competitiveness. The Company has established an industry-leading integrated antibody drug R&D platform, which includes the following key components: i) high-throughput monoclonal antibody discovery, screening and developability evaluation system: with an annual capacity to support early discovery for over 10 monoclonal antibody projects, it efficiently identifies candidate molecules with potential differentiation advantages; ii) innovative bispecific antibody design and development platform: built on the existing monoclonal antibody pipeline, it enables rapid and efficient development of bispecific antibodies, significantly shortening R&D timelines; iii) comprehensive CMC development system: equipped with full-process capabilities, including antibody physicochemical characterization, production cell line construction, process development and formulation optimization; iv) translational medicine research platform: covering clinical pharmacology and translational research from preclinical to clinical stages. With the core mission of improving patient clinical benefits and medication adherence, we highlight the differentiated advantages of our products, and actively explore combination therapies involving bispecific antibodies in our development strategy. Our R&D efforts are primarily focused on the following areas:

- ***Respiratory Diseases***

  Addressing the transformative need for disease-modifying therapy (DMT) in asthma and chronic obstructive pulmonary disease (COPD), we aim to develop superior long-term treatment options that can delay, halt or even reverse disease progression while maintaining sustained efficacy to achieve the goal of clinical remission;

- ***Inflammatory Bowel Disease (IBD)***

  To overcome the limitations of current therapies in achieving clinical remission, we are developing innovative products that significantly improve both clinical and endoscopic remission rates and meet the alternative treatment needs of patients who have been treated with biologics;

- ***Skin Diseases***

  Focusing on unmet clinical needs, including:

  Atopic Dermatitis (AD): Exploring novel treatment strategies to achieve rapid symptom and lesion relief, reduce relapse risk, and significantly prolong time to recurrence;

  Chronic Spontaneous Urticaria (CSU): Developing next-generation drugs capable of immediate symptom control, even in treatment-refractory patients.

The overall goal of bispecific antibody product development is to enhance drug efficacy, optimize dosing intervals, improve adherence, and reduce medication costs.

For the six months ended June 30, 2025, our total R&D costs amounted to approximately RMB151.39 million.

The following table sets forth a breakdown of our total R&D costs:

	For the six months ended June 30	
	2025	2024
	RMB'000	*RMB'000*
Staff costs	**26,826**	40,683
Depreciation and amortization	**4,987**	10,921
Third party contracting costs	**106,209**	79,636
Raw materials and consumables	**6,130**	6,352
Others	**7,242**	7,634
Total	**151,394**	145,226

Manufacturing and Commercialization

Our production facility is meticulously constructed in strict compliance with the current Good Manufacturing Practice (cGMP) standards of China, the United States, and the European Union. At present, we have successfully obtained the Drug Manufacturing License. Moreover, in November 2024, the facility of Cellularforce passed the GMP compliance inspection for SAILEXIN drug substance and drug product manufacture organized by the NMPA. The facility is located at our headquarters in Taizhou, Jiangsu and occupies 57,977 sq.m. of land. Our manufacturing site has one drug substance production line and two formulation production lines. The drug substance production line has four 2,000 L single-use bioreactors and relevant downstream purification production line with an annual manufacturing capacity of approximately 300 kg therapeutic antibodies. The formulation production lines have one vial production line for 2 ml, 10 ml and 30 ml specifications, with a manufacturing capacity of 18,000 vials/hour, and one prefilled syringe fill-finish and packaging production line for 1 ml and 2 ml specifications, with a manufacturing capacity of 9,000 syringes/hour. Our self-owned cGMP-standard manufacturing capability, coupled with our strong R&D capability, will allow us to achieve reliable cost control and ensure stable clinical and commercialized drug supply to any supply chain disruptions.

Going forward, we will continue to leverage the strong networking of physician resources from our strategic partners to connect with participants in the drug sales and distribution chain, and also to solidify the foundation for commercial launches of our drug candidates. In the future, we plan to build a relatively small, indication-specialized in-house commercialization team, beginning with indications with relatively limited and concentrated patient populations treated in a small number of key hospitals, based on our deep understanding of these indications and physician resources.

Intellectual Property

As of June 30, 2025, we held 50 patents in China, including 40 invention patents and 10 utility models, as well as 16 patents overseas. As of the same date, we also had 47 patent applications pending in China and overseas. In particular, with respect to our Core Products, we had 9 registered patents and 1 pending patent application for QX002N and 8 registered patents and 1 pending patent application for QX005N. All of our patents and patent applications are self-owned. As of the June 30, 2025, we had registered 94 trademarks in the PRC and Hong Kong and we submitted applications for 1 trademark in the PRC. As of the same date, we were also the registered owner of 21 domain names in the PRC. As of June 30, 2025, we had not been involved in any material proceeding in respect of, and we had not received notice of any material claim of infringement of, any intellectual property rights that may be threatened or pending, in which we may be a claimant or a respondent that may have a material adverse impact on us.

Employees and Remuneration

As of June 30, 2025, the Group had 337 employees, all of whom were based in China.

The number of employees of the Group varies from time to time depending on need. The remuneration package of the Group's employees includes salary, bonus and equity incentives, which are generally determined by their qualifications, industry experience, position and performance. Our Company makes contributions to social insurance and housing provident funds in accordance with relevant laws and regulations.

Our Company has conditionally adopted an Employee Share Incentive Scheme to eligible participants for their contribution or potential contribution to the Group.

For the six months ended June 30, 2025, the Group did not experience any material labor disputes or strikes that may have a material adverse effect on the Group's business, financial condition or results of operations, or any difficulty in recruiting employees.

Future Outlook

Going forward, we plan to pursue the following strategies, which we believe will further strengthen our core competitive strengths and enable us to capture rising business opportunities:

- Continuously solidify our foundation to strive for the goal that at least five products will be approved for marketing by 2030 and significant sales volume achieved;
- Advance the R&D of bispecific antibody drug candidates and strategically expand our pipeline to meet the substantial therapeutic needs in the respiratory, IBD and dermatology fields;
- Continue to optimize CMC quality management system and improve production efficiency and enhance manufacturing capacity utilization;
- Cooperate with established pharmaceutical companies in commercialization;
- Firmly implement the globalization strategy and further establish more overseas partnerships; and
- Continue to recruit and develop talent.

Our Directors confirm that there has been no material adverse change in the financial or trading position or prospects of our Group since June 30, 2025 and up to the date of this announcement.

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME – Unaudited

For the six months ended June 30, 2025

		Six months ended 30 June	
		2025	2024
	Note	***RMB'000***	*RMB'000*
Revenue	*3*	**206,486**	44,919
Cost of sales		**(28,868)**	(7,163)
Gross profit		**177,618**	37,756
Other income	*4*	**7,162**	7,402
Other net (loss)/gain		**(3,294)**	1,165
Selling and distribution expenses		**(408)**	–
Administrative expenses		**(48,269)**	(70,331)
Research and development expenses		**(151,394)**	(145,226)
Loss from operations		**(18,585)**	(169,234)
Finance costs	*5(a)*	**(12,385)**	(13,942)
Loss before taxation	*5*	**(30,970)**	(183,176)
Income tax	*6(a)*	**37**	37
Loss for the period		**(30,933)**	(183,139)
Attributable to:			
Equity shareholders of the Company		**(28,333)**	(172,116)
Non-controlling interests		**(2,600)**	(11,023)
Loss for the period		**(30,933)**	(183,139)
Other comprehensive income for the period, net of tax		**–**	–
Total comprehensive income for the period, net of tax		**(30,933)**	(183,139)
Attributable to:			
Equity shareholders of the Company		**(28,333)**	(172,116)
Non-controlling interests		**(2,600)**	(11,023)
Total comprehensive income for the period		**(30,933)**	(183,139)
Loss per share	*7*		
Basic and diluted *(RMB)*		**(0.13)**	(0.79)

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At June 30, 2025

	Note	**At 30 June 2025**	At 31 December 2024
		RMB'000	*RMB'000*
		(Unaudited)	(Audited)
Non-current assets			
Property, plant and equipment	*8*	**299,842**	312,315
Right-of-use assets		**21,373**	21,743
Intangible assets		**2,904**	3,473
Equity investment designated at fair value through other comprehensive income ("**FVOCI**")	*9*	**96,794**	–
Other non-current assets		**32,178**	29,621
		453,091	367,152
Current assets			
Inventories and other contract costs	*10*	**32,800**	8,774
Trade and other receivables	*11*	**87,364**	51,824
Financial assets measured at fair value through profit or loss ("**FVPL**")	*12*	**20,073**	195,439
Time deposits	*13*	**39,500**	–
Cash and cash equivalents	*13*	**499,324**	360,688
		679,061	616,725
Current liabilities			
Trade and other payables	*14*	**241,790**	208,794
Contract liabilities	*15*	**21,498**	9,364
Interest-bearing borrowings	*16*	**186,345**	210,582
Lease liabilities		**1,409**	1,421
		451,042	430,161
Net current assets		**228,019**	186,564
Total assets less current liabilities		**681,110**	553,716

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Continued)

At June 30, 2025

	Note	**At 30 June 2025**	At 31 December 2024
		RMB'000	*RMB'000*
		(Unaudited)	(Audited)
Non-current liabilities			
Non-current interest-bearing borrowings	*16*	**447,773**	315,120
Deferred income		**16,797**	16,734
Lease liabilities		**408**	472
Deferred tax liabilities		**303**	340
		465,281	332,666
NET ASSETS		**215,829**	221,050
CAPITAL AND RESERVES			
Share capital		**222,072**	222,072
Reserves		**4,284**	6,905
Total equity attributable to equity shareholders of the Company		**226,356**	228,977
Non-controlling interests		**(10,527)**	(7,927)
TOTAL EQUITY		**215,829**	221,050

CONDENSED CONSOLIDATED CASH FLOW STATEMENT – Unaudited

For the six months ended June 30, 2025

		Six months ended June 30	
		2025	2024
	Note	***RMB'000***	*RMB'000*
Net cash used in operating activities		**(91,764)**	(66,846)
Net cash generated from investing activities		**137,730**	3,389
Net cash generated from financing activities		**95,814**	314,451
Net increase in cash and cash equivalents		**141,780**	250,994
Cash and cash equivalents at the beginning of the period		**360,688**	216,300
Effect of foreign exchange rate changes		**(3,144)**	1,142
Cash and cash equivalents at the end of the period	*11*	**499,324**	468,436

NOTES

1 BASIS OF PREPARATION

This interim financial report has been prepared in accordance with the applicable disclosure provisions of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, including compliance with International Accounting Standard ("**IAS**") 34, *Interim financial reporting*, issued by the International Accounting Standards Board (IASB). It was authorised for issue on 15 August 2025.

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2024 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2025 annual financial statements. Details of any changes in accounting policies are set out in note 2.

The preparation of an interim financial report in conformity with IAS 34 requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses on a year to date basis. Actual results may differ from these estimates.

This interim financial report contains condensed consolidated financial statements and selected explanatory notes. The notes include an explanation of events and transactions that are significant to an understanding of the changes in financial position and performance of Qyuns Therapeutics Co., Ltd. (the "**Company**") and its subsidiaries (together, the "**Group**") since the 2024 annual financial statements. The condensed consolidated interim financial statements and notes thereon do not include all of the information required for a full set of financial statements prepared in accordance with International Financial Reporting Standards (IFRSs).

The interim financial report is unaudited, but has been reviewed by KPMG in accordance with Hong Kong Standard on Review Engagements 2410, *Review of interim financial information performed by the independent auditor of the entity*, issued by the Hong Kong Institute of Certified Public Accountants ("**HKICPA**").

The financial information relating to the financial year ended 31 December 2024 that is included in the interim financial report as comparative information does not constitute the Company's statutory annual consolidated financial statements for that financial year but is derived from those financial statements. The Company's annual consolidated financial statements for the year ended 31 December 2024 are available from the Company's registered office. The auditors have expressed an unqualified opinion on those financial statements in their report dated 28 March 2025.

2 CHANGES IN ACCOUNTING POLICIES

The Group has applied the amendments to IAS 21, *The effects of changes in foreign exchange rates – Lack of exchangeability* issued by the IASB to this interim financial report for the current accounting period. The amendments do not have a material impact on this interim report as the Group has not entered into any foreign currency transactions in which the foreign currency is not exchangeable into another currency.

The Group has not applied any new standard or interpretation that is not yet effective for the current accounting period.

3 REVENUE

(a) Disaggregation of revenue

The Group is principally engaged in the research and development, manufacturing, and commercialization of biologic therapies for autoimmune and allergic diseases. During the period ended 30 June 2025, the Group's revenue was mainly derived from license agreements by granting licenses of certain intellectual properties to customers, and providing research and development services in relation to certain licensed products to the customers, etc.

Disaggregation of revenue from contracts with customers by major products or service lines and the timing of revenue recognition is as follows:

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
Revenue from contracts with customers within the scope of IFRS 15		
Revenue from license agreements	**180,770**	44,919
Revenue from provision of research and development services and other services	**22,000**	–
Sales of products	**3,716**	–
	206,486	44,919
Disaggregated by timing of revenue recognition		
– Point in time	**200,697**	30,189
– Over time	**5,789**	14,730
	206,486	44,919

(b) Segment and geographical information

For the purpose of making decisions about resources allocation and performance assessment, the Group's management focuses on the operating results of the Group as a whole. As such, the Group's resources are integrated, and no discrete operating segment information is available. Accordingly, no operating segment information is presented.

The following table sets out information about the geographical location of the Group's revenue from external customers.

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
The People's Republic of China (the "**PRC**")	**54,017**	44,919
The United States	**152,469**	–
	206,486	44,919

4 OTHER INCOME

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
Government grants[(i)]	**1,575**	5,539
Interest income from bank deposits	**4,030**	3,521
Net realised and unrealised gains on financial assets measured at FVPL	**1,557**	2,188
Others	**–**	(3,846)
	7,162	7,402

(i) Government grants mainly represent government subsidies for encouragement of research and development activities and compensation on the incurred interest expenses of bank loans, which were recognised in profit or loss when received.

5 LOSS BEFORE TAXATION

Loss before taxation is arrived at after charging:

(a) Finance costs

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
Interest on interest-bearing borrowings	**10,507**	13,912
Interest on lease liabilities	**30**	30
Other finance costs	**1,848**	–
Total finance costs on financial liabilities not at FVPL	**12,385**	13,942

(b) Other items

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
Amortisation cost of intangible assets	**569**	478
Depreciation charge of property, plant and equipment	**14,698**	14,796
Depreciation charge of right-of-use assets	**704**	1,054
Total amortisation and depreciation	**15,971**	16,328
Provisions for write-down of inventories and other contract costs	**1,948**	2,422
Equity-settled share-based payment expenses	**25,712**	50,638
Research and development expenses[(i)]	**151,394**	145,226

(i) During the six months ended 30 June 2025, research and development expenses include staff costs and depreciation and amortisation expenses of RMB31,813,000 (six months ended 30 June 2024: RMB51,604,000), which are also included in the respective total amounts disclosed separately above.

6 INCOME TAX

(a) Taxation in the consolidated statements of profit or loss represents:

	Six months ended 30 June	
	2025	2024
	RMB'000	*RMB'000*
Current tax – PRC	**–**	–
Tax Deferred taxation	**(37)**	(37)
	(37)	(37)

(i) Statutory tax rate

Pursuant to the Enterprise Income Tax (the "**EIT**") Law of the PRC (the "**EIT Law**"), the Company and its PRC subsidiaries are liable to EIT at a rate of 25% unless otherwise specified.

(ii) Preferential tax

Under the EIT Law of the PRC and its relevant regulation, an additional 100% of qualified research and development expenses incurred would be allowed to be deducted from the taxable income for the year ending 31 December 2025.

7 LOSS PER SHARE

The calculation of basic loss per share is based on the loss attributable to ordinary equity shareholders of the Company of RMB28,333,000 (six months ended 30 June 2024: RMB172,116,000) and the weighted average of 222,072,000 ordinary shares (six months ended 30 June 2024: 216,776,000) in issue during the period.

Share options and restricted shares granted by the Company were not included in the calculation of diluted loss per share because their effect would have been anti-dilutive. Accordingly, diluted loss per share for the period ended 30 June 2024 and 2025 were the same as basic loss per share of the respective periods.

8 PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2025, the Group acquired items of plant and equipment with a cost of RMB2,274,000 (six months ended 30 June 2024: RMB515,000).

The Group's land use right and manufacturing facilities in Taizhou have been pledged as collateral in August 2023 under the Group's borrowing arrangements with the carrying amount of RMB222,560,000 at 30 June 2025 (six months ended 30 June 2024: RMB230,798,000).

9 EQUITY INVESTMENT DESIGNATED AT FVOCI

	At 30 June 2025	At 31 December 2024
	RMB'000	*RMB'000*
Unlisted equity investment, at fair value	**96,794**	–

On 23 April 2025, the Group entered into a license-out agreement (the "**License Agreement**") with Caldera Therapeutics, Inc. ("**Caldera**"), under which Caldera was granted an exclusive right to develop and commercialize the product QX030N globally. Pursuant to the License Agreement, the Group received a non-refundable upfront payment of USD10,000,000 and approximately 24.88% of equity interest in Caldera during the six months ended 30 June 2025.

As the Group does not participate in or influence the financial and operating policy decisions of Caldera, the Group concluded that it has no significant influence over Caldera and measured this equity investment at fair value. In addition, the Group designated its investment in Caldera at FVOCI, as the investment is held for strategic purposes. No dividends were received on this investment during the period.

10 INVENTORIES AND OTHER CONTRACT COSTS

As at 30 June 2025, inventories and other contract costs consisted of inventories of RMB6,483,000 and other contract costs for fulfilling existing contracts of RMB26,317,000. All of the capitalised contract costs are expected to be recovered within one year.

During the six months ended 30 June 2025, RMB1,948,000 (six months ended 30 June 2024: RMB2,422,000) has been recognised as a reduction in the amount of inventories and other contract costs. The write-down was included in 'cost of sales' in the consolidated statement of profit or loss and other comprehensive income.

11 TRADE AND OTHER RECEIVABLES

	At 30 June 2025	At 31 December 2024
	RMB'000	*RMB'000*
Within 6 months	**67,632**	26,281
Trade receivables	**67,632**	26,281
Prepaid expenses	**18,196**	24,520
Deposits	**563**	424
Interest receivables	**762**	491
Other debtors	**211**	108
Trade and other receivables	**87,364**	51,824

Trade receivables are generally due within 60 to 180 days from the date of billing. All of the trade and other receivables are expected to be recovered or recognised as expense within one year.

12 FINANCIAL ASSETS MEASURED AT FVPL

	At 30 June 2025	At 31 December 2024
	RMB'000	*RMB'000*
Wealth management products	**20,073**	195,439

Financial assets measured at FVPL comprise the investments in wealth management products purchased from banks in the PRC.

13 TIME DEPOSITS AND CASH AND CASH EQUIVALENTS

	At 30 June 2025	At 31 December 2024
	RMB'000	*RMB'000*
Time deposits with original terms over three months	**39,500**	–
Cash at bank	**291,706**	197,110
Time deposits with original terms within three months	**207,618**	163,578
Cash and cash equivalents	**499,324**	360,688

14 TRADE AND OTHER PAYABLES

As of the end of the reporting period, the ageing analysis of trade creditors (which are included in trade and other payables), based on the invoice date, is as follows:

	At 30 June 2025	At 31 December 2024
	RMB'000	*RMB'000*
Within 12 months	**126,577**	110,885
Trade payables	**126,577**	110,885
Payroll payables	**26,540**	33,373
Payables for purchases of property, plant and equipment	**5,089**	6,758
Accrued listing expenses	**478**	3,290
Other payables and accruals[(i)]	**83,106**	54,488
	241,790	208,794

(i) In July 2024, the Company entered into a cooperation agreement (the "**QX005N Agreement**") with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (杭州中美華東製藥有限公司) ("**Zhongmei Huadong**"), one of the shareholders of the Company, with respect to the joint development and commercialisation of the product QX005N. Pursuant to QX005N Agreement, the Company has granted to Zhongmei Huadong, in the authorised territory and in the authorised fields, (i) an exclusive right to jointly develop QX005N; (ii) an exclusive optional right to promote QX005N (the "**Optional Right**"); and (iii) a right of first refusal for the transfer of marketing authorization holder ("**MAH**") of QX005N. In the event that Zhongmei Huadong chooses not to exercise the Optional Right, the Company shall return the payment received in full to Zhongmei Huadong, and shall pay Zhongmei Huadong an interest of 5% per annum on the entire amount received.

Pursuant to the QX005N Agreement, Zhongmei Huadong has paid a milestone payment of RMB45,000,000 to the Company and incurred on behalf of the Company RMB24,377,000 clinical development fees for QX005N as of 30 June 2025 (2024: RMB11,419,000), which was recognised as financial liabilities of the Company as at 30 June 2025.

15 CONTRACT LIABILITIES

	At 30 June 2025	At 31 December 2024
	RMB'000	*RMB'000*
Receipts in advance from customers	**21,498**	9,364

16 INTEREST-BEARING BORROWINGS

	At 30 June 2025	At 31 December 2024
	RMB'000	*RMB'000*
Unsecured short-term bank loans[(i)]	**104,583**	179,483
Current proportion of unsecured long-term bank loans[(i)]	**53,954**	3,291
Current proportion of secured long-term bank loans[(ii)]	**27,808**	27,808
Within 1 year or on demand	**186,345**	210,582
Unsecured long-term bank loans[(i)]	**258,068**	111,700
Secured long-term bank loans[(ii)]	**189,705**	203,420
Non-current	**447,773**	315,120
	634,118	525,702

(i) As at 30 June 2025, the unsecured short-term bank loans and unsecured long-term bank loans bear interest rate from 2.4% to 3.8% (2024: 3.0% to 3.8%).

(ii) In June 2024, Cellularforce, a subsidiary of the Company, entered into a loan arrangement with two commercial banks in the PRC to support the construction of its manufacturing facilities. The loan was secured by Cellularforce's land use right and its manufacturing facilities in Taizhou and guaranteed by the Company, and bear interest rate of 3.5% as at 30 June 2025 (2024: 3.9%).

17. DIVIDENDS

No dividends were paid or declared by the Company or any of its subsidiaries (six months ended June 30, 2024: nil).

FINANCIAL REVIEW

The following discussion is based on, and should be read in conjunction with, the financial information and the notes included elsewhere in this announcement.

Analysis of our Key Items of our Results of Operations

Revenue

The Group's revenue amounted to RMB206.49 million for the six months ended June 30, 2025, mainly including: (i) revenue from licensing agreement, including upfront fee and non-cash consideration of approximately 24.88% equity interest in Caldera in relation to overseas licensing of QX030N, as well as the milestone fee for the first patient enrollment in Phase III of QX004N, totalling RMB180.77 million; and (ii) revenue from CDMO services and provision of R&D services for the QX004N and QX008N projects of approximately RMB22.00 million.

Cost of Sales

Our Group's cost of sales amounted to RMB28.87 million for the six months ended June 30, 2025, which mainly consists of (i) relevant costs incurred from CDMO services; (ii) relevant costs incurred from R&D services provided for QX004N and from overseas licensing of QX030N; and (iii) provisions for write-down of inventories and other contract costs.

Other Net Loss

For the six months ended June 30, 2025, the Company's other net loss amounted to RMB3.29 million, which primarily represented foreign exchange losses of RMB3.17 million resulting from the depreciation of HKD and USD against RMB.

Administrative Expenses

Our administrative expenses decreased by 31.36% from RMB70.33 million for the six months ended June 30, 2024 to RMB48.27 million for the six months ended June 30, 2025, primarily attributable to a decrease in equity-settled share-based payment expenses of RMB19.06 million.

Research and Development Expenses

Our R&D expenses increased by 4.25% from RMB145.23 million for the six months ended June 30, 2024 to RMB151.39 million for the six months ended June 30, 2025, including decrease of RMB5.87 million in amortization of equity-settled share-based payment and increase of RMB12.04 million in R&D expenses primarily attributable to the increase in clinical trial costs resulting from the advancement of clinical trials of the Company.

Finance Costs

Our finance costs decreased by 11.17% from RMB13.94 million for the six months ended June 30, 2024 to RMB12.39 million for the six months ended June 30, 2025, primarily attributable to the net fact that (i) in 2024, we recognized a one-time amortization of syndicated loan expenses of RMB3.56 million related to the replacement of syndicated loan for the construction of our Phase I manufacture facility; and (ii) in 2025, we recognized interest expenses of approximately RMB1.85 million incurred for QX005N.

Analysis of our Key Items of our Financial Position

Non-current Assets

Our non-current assets increased from RMB367.15 million as of December 31, 2024, to RMB453.09 million as of June 30, 2025, primarily due to the recognition of equity investment designated at fair value through other comprehensive income with the appraised value of approximately RMB96.79 million for the approximately 24.88% equity interest in Caldera acquired under the QX030N overseas licensing agreement.

Net Current Assets

The increase in our net current assets from RMB186.56 million as of December 31, 2024 to RMB228.02 million as of June 30, 2025 was primarily attributable to a net cash inflow from increased non-current interest-bearing borrowings of RMB132.65 million and the upfront and milestone fee received of RMB74.04 million for the out-licensing deals of QX030N and QX008N, which increased the Company's cash reserves, partially offset by operating expenses incurred during the current period.

Inventories and Other Contract Costs

The increase in our inventories and other contract costs from RMB8.77 million as of December 31, 2024 to RMB32.80 million as of June 30, 2025 primarily represented the SAILEXIN inventory, raw materials and contract costs for external CDMO services. The increase in the balance of inventory and other contract costs was mainly due to the increase of capitalised contract cost with growth of CDMO business under development as of June 30, 2025, compared to December 31, 2024.

Trade and Other Receivables

Our trade and other receivables increased by RMB35.54 million from RMB51.82 million as of December 31, 2024 to RMB87.36 million as of June 30, 2025, mainly attributable to the receivables of RMB58.00 million from QX004N out-licensing projects as of the end of June 2025.

Trade and Other Payables

Our trade and other payables increased from RMB208.79 million as of December 31, 2024 to RMB241.79 million as of June 30, 2025, primarily attributable to an increase in clinical trial expenses payable by the Company of approximately RMB30.00 million with advancement of clinical trials.

Contract Liabilities

We had contract liabilities of RMB21.50 million as of June 30, 2025, mainly represented part of the upfront fee received for the overseas licensing project of QX030N, which has not yet met the conditions for revenue recognition. The payment was recorded as contract liabilities and is expected to be recognized as revenue upon achievement of delivery condition under the respective contract.

Contingent Liabilities

The Group had no material contingent liabilities as of June 30, 2025 (December 31, 2024: Nil).

Liquidity and Capital Resources

We mainly relied on capital contributions by our shareholders, equity financing, upfront and milestone payment from our licensing-out deals and income from external CDMO services as the major sources of liquidity as well as bank and other borrowings. As part of our treasury policy, our management monitors and maintains a level of cash and bank balances deemed adequate to finance our operations and mitigate the effects of fluctuations in cash flows. As our business develops and expands, we expect to generate more cash from profit sharing and product supply of SAILEXIN as well as debt financing, refinancing, milestone fee income from licensing-out deals with QX030N, QX008N and QX004N, and cost sharing from joint development of QX005N with Zhongmei Huadong.

We have optimized our bank loan structure. As of June 30, 2025, the balance of working capital loan with terms of 2 to 3 years accounted for 74.9% of the total working capital loan balance (December 31, 2024: 39.1%).

As of June 30, 2025, the unutilized credit facility for working capital use available to us amounted to RMB180.73 million.

Indebtedness

We had interest-bearing borrowings of approximately RMB525.70 million and RMB634.12 million as of December 31, 2024 and June 30, 2025, respectively, which primarily consist of a secured bank loan used to support the construction of our manufacturing facility and unsecured bank loans to support our operation.

The total amount of loans with a fixed interest rate was RMB172.56 million as of June 30, 2025 (December 31, 2024: RMB200.00 million). The fixed interest rate ranged from 2.4% to 3.8% per annum as of June 30, 2025 (2024: 3.0% to 3.8% per annum).

Key Financial Ratios

Our current ratio increased from 1.4 as of December 31, 2024 to 1.5 as of June 30, 2025, mainly attributable to the increase in receivables in relation to license-out agreement by RMB35.49 million as of June 30, 2025, compared to the end of 2024.

Gearing Ratio

In order to better interpret the gearing ratio, the Company decided to adjust the gearing ratio to be calculated based on total liabilities divided by total assets and multiplied by 100%. Our gearing ratio was approximately 80.9% as of June 30, 2025 (December 31, 2024: 77.5%). The change compared to the end of last year was mainly due to the increase in working capital loans draw-down during the current period.

Charges on Assets

The Group's land use right and manufacturing facilities in Taizhou have been pledged as collateral in July 2024 under the 2024 Secured Long-Term Loan. The details of the pledged asset of the Group are set out in Note 8 to the Consolidated Financial Statements.

MARKET RISKS

The Group is exposed to various types of market risks and other financial risks, including cash flow and fair value interest rate risk, credit risk, liquidity risk and currency risk.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to our Group. Our credit risk is primarily attributable to trade and other receivables. Our exposure to credit risk arising from cash and cash equivalents and wealth management products is limited because the counterparties are reputable banks or financial institution, for which we consider to have low credit risks.

The Group's exposure to credit risk is influenced mainly by the individual characteristics of each customer. As of June 30, 2025, approximately 99.95% of the total trade receivables were due from our five largest debtors. The Group will review and monitor the level of exposure to ensure that follow-up actions are taken to recover overdue debts. In addition, at the end of each reporting year, the Group performs impairment assessment under expected credit loss model so as to ensure that adequate impairment losses are made. The carrying amounts of trade receivables and other receivables represent the Group's maximum exposure to credit risk in relation to financial assets.

Liquidity risk

Individual operating entities within our Group are responsible for their own cash management, including the short-term investment of cash surpluses and the raising of loans to cover expected cash demands, subject to approval by our Shareholders when the borrowings exceed certain predetermined levels of authority. Our policy is to regularly monitor our liquidity requirements and our compliance with lending covenants, to ensure that we maintain sufficient reserves of cash and readily realizable securities and adequate committed lines of funding from major financial institutions to meet our liquidity requirements in the short and longer term.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. Our interest rate risk arises primarily from long-term borrowings. Borrowings issued at variable rates and fixed rates expose our Group to cash flow interest rate risk and fair value interest rate risk respectively. We regularly review our strategy on interest rate risk management in the light of the prevailing market condition. The Group had not used any interest rate swaps to hedge its exposure to interest rate risk for the six months ended June 30, 2025.

Foreign currency risk

We are exposed to currency risk primarily through deposits with bank which give rises to cash balances that are denominated in a foreign currency, i.e., a currency other than the functional currency of the operations to which the transactions relate. The currencies primarily relevant to this risk are the U.S. dollars and Hong Kong dollars. The Group does not enter into any hedging transactions to manage the potential fluctuation in foreign currency.

CAPITAL STRUCTURE

The shares of our Company were listed on Main Board of the Stock Exchange on the Listing Date. Save as disclosed in this announcement, there has been no material change in the capital structure of our Company since that date.

SIGNIFICANT INVESTMENTS AND MATERIAL ACQUISITIONS AND DISPOSALS

On 23 April 2025, the Group entered into a license-out agreement (the "**License Agreement**") with Caldera Therapeutics, Inc. ("**Caldera**"), under which Caldera was granted an exclusive right to develop and commercialize the product QX030N globally. In connection with the License Agreement, the Company and Caldera have also entered into a share purchase agreement (the "**SPA**") on the same date of the License Agreement, under which the Group agrees to acquire the equity interest in Caldera Therapeutics. Pursuant to the License Agreement, the Group received a non-refundable upfront payment of USD10,000,000 and approximately 24.88% of equity interest in Caldera. As at the date of the SPA, Caldera had no revenue or profit and none of the applicable percentage ratios under the Listing Rules in respect of such transactions under the SPA exceeded 5%. Accordingly, such a transaction was not subject to the announcement or shareholder approval requirements under Chapter 14 of the Listing Rules. Please refer to the announcement of the Company dated April 24, 2025 for details.

The acquisition of approximately 24.88% equity interest in Caldera under the SPA was completed on May 14, 2025. As of June 30, 2025, according to the Equity Valuation Report issued by Asia-Pacific Appraisal, the fair market value of the equity interest in Caldera, as mentioned above, was assessed at USD13,521,314 (equivalent to RMB96,793,678.40), representing over 5% of the Company's total asset value. Please refer to Note 9 to the Consolidated Financial Statements for details.

In order to effectively utilize the Group's idle funds and generate better returns, during the Reporting Period, the Group subscribed for and held various wealth management products (primarily principal-protected floating return wealth management products) managed by local branches of national commercial banks or regional commercial banks in Jiangsu province. We believe that investment in low-risk financial products, such as wealth management products, helps us make better use of our cash while ensuring sufficient cash flow for business operations or capital expenditures. Considering that these wealth management products are short-term and principal-protected, we believe our credit risk exposure is limited.

During the Reporting Period, the Group held two wealth management products with the value exceeding 5% of the Group's total assets as of June 30, 2025, details of which are as follows:

Product name	Confirmation date of subscription	Maturity date	Principal amount of subscription	Expected yield of the product (per annum)	Product type	Risk level of the product
Liduoduo Corporate Stable Profit 25JG5700 (Three Level Bullish) RMB Public Structured Deposit	March 10, 2025	June 10, 2025	RMB60 million	The product has a guaranteed yield of 0.85% and a floating yield of 0% or 0.90% (mid-range floating yield) or 1.10% (high-range floating yield)	Principal-guaranteed floating-yield type	Low risk (internal risk assessment results of PDB, for reference only)
Liduoduo Corporate Stable Profit 25JG3094 (Three-Month Early Bird) RMB Public Structured Deposit	March 10, 2025	June 10, 2025	RMB80 million	The product has a guaranteed yield of 0.85% and a floating yield of 0% or 1.15% (mid-range floating yield) or 1.35% (high-range floating yield)	Principal-guaranteed floating-yield type	Low risk (internal risk assessment results of PDB, for reference only)

For further details about the above subscriptions, please refer to the announcement of the Company dated March 7, 2025.

Our investment strategy is relatively prudent. We have implemented a series of treasury policies and internal control policies and rules setting forth overall principles, focusing on the appreciation of capital and supporting our liquidity needs in a manner that is consistent with our overall financial goals and risk considerations. Prior to making an investment, we ensure that there remains sufficient working capital for our business needs, operating activities, R&D and capital expenditures after purchasing such wealth management products. We adopt a prudent approach in selecting financial products. Our investment decisions are made on a case-by-case basis and after due and careful consideration of a number of factors, such as duration of the investment and the expected returns. We generally limit our investments to wealth management products described as having low level risks and offered by major and reputable commercial banks, and we do not permit investment in stock for trading or speculative purposes. In addition, all investments in wealth management products should comply with applicable laws and regulations. Under our investment policy, our finance department personnel should prepare wealth management products purchase plan, based on anticipated expenditures, operational expenses, our cash and bank balances and information of the relevant wealth management products, for the head of finance department and general manager to review.

Save as disclosed above, our Company had no other significant investments during the six months ended June 30, 2025.

FUTURE PLANS FOR MATERIAL INVESTMENTS AND CAPITAL ASSETS

Save as disclosed in the section headed "Future Plans and Use of Proceeds" of the Prospectus and herein, the Group did not have plan for material investments and capital assets as of the date of this announcement.

MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES, ASSOCIATES AND JOINT VENTURES

The Group did not have any material acquisition or disposal of subsidiaries, associates and joint ventures during the six months ended June 30, 2025.

CHANGE IN INFORMATION OF DIRECTORS AND SUPERVISORS

During the Reporting Period, there is no change in the information of the Directors and Supervisors of the Company which are required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

H SHARE FULL CIRCULATION

The Company completed the conversion of 17,322,400 Unlisted Shares into H Shares and the listing thereof on March 27, 2025 (the "**Conversion and Listing**"). The Company received the Notice of the Full Circulation Registration of the Domestic Unlisted Shares of Qyuns Therapeutics Co., Ltd.*（關於江蘇荃信生物醫藥股份有限公司境內未上市股份「全流通」備案通知書）from the China Securities Regulatory Commission on January 20, 2025 and the listing approval from the Stock Exchange on March 13, 2025 in respect of the Conversion and Listing. The listing of the converted H Shares on the Stock Exchange has commenced at 9:00 a.m. on March 28, 2025 as scheduled. For details, please refer to the announcements of the Company dated October 28, 2024, January 21, 2025, March 13, 2025 and March 27, 2025.

EXCLUSIVE LICENSE AGREEMENT WITH CALDERA THERAPEUTICS FOR THE DEVELOPMENT AND COMMERCIALIZATION OF QX030N

On April 23, 2025, the Company and Caldera Therapeutics, Inc. have entered into the License Agreement, under which Caldera Therapeutics, Inc. is granted an exclusive right to develop and commercialize QX030N globally. Please refer to the announcement of the Company dated April 24, 2025 for details.

AMENDMENT OF ARTICLES OF ASSOCIATION

On April 30, 2025, the Company proposed to amend its Articles of Association, pursuant to the current effective "Company Law of the People's Republic of China", "Guidelines for Articles of Association of Listed Companies", "Measures for the Administration of Independent Directors", certain recent amendments to the Listing Rules and other relevant laws and regulations (the "**Amendment of Articles**"). For further details, please refer to the announcement of the Company dated April 30, 2025 and the circular of the Company dated April 30, 2025.

At the annual general meeting of the Company held on June 20, 2025, the shareholders of the Company approved the Amendment of Articles by way of special resolution.

OTHER INFORMATION

PURCHASE, SALE OR REDEMPTION OF OUR COMPANY'S SHARES OR SALE OF TREASURY SHARES

During the Reporting Period and as of the date of this announcement, neither our Company nor any of its subsidiaries purchased, sold or redeemed any listed securities (including sale of treasury shares) (as defined in the Listing Rules) of our Company.

As at the date of this announcement, the Company did not hold any treasury shares (as defined in the Listing Rules).

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

Our Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its own code of conduct for dealing in securities of our Company by the Directors and Supervisors.

Specific enquiry has been made of all the Directors and Supervisors, all the Directors and Supervisors have confirmed that they have complied with the Model Code during the Reporting Period. No incident of non-compliance by the Directors and Supervisors was noted by the Company during the Reporting Period.

EMOLUMENT POLICY

The emoluments of the Directors, Supervisors and senior management of the Group are determined by the Board with reference to the respective responsibilities and duties, experience, individual performance, and time devoted to the Group and may be adjusted upon the recommendation of the Remuneration and Appraisal Committee. The Remuneration and Appraisal Committee was set up for reviewing our Company's emolument policy and structure of all remuneration of the Directors, Supervisors and senior management of our Company.

CORPORATE GOVERNANCE PRACTICES

The Board is committed to achieving high corporate governance standards. The Board believes that high corporate governance standards are essential in providing a framework for our Company to safeguard the interests of the Shareholders, enhance corporate value, formulate its business strategies and policies, and improve its transparency and accountability.

Save as disclosed below, our Company has adopted the principles and Code Provisions of the CG Code contained in Appendix C1 to the Listing Rules as the basis for the corporate governance practices of the Company during the Reporting Period and up to the date of this announcement. During the Reporting Period, the Company has complied with all applicable Code Provisions of the CG Code save and except for the following deviation:

Under the Code Provision C.2.1 of Part 2 of the CG Code, the roles of chairman and chief executive shall be separate and shall not be performed by the same individual. The Chairman and General Manager (equivalent to chief executive officer) of our Company are held by Mr. Qiu who is the founder of our Company and has extensive experience in the industry. Having served in our Company as the general manager since the very early stage of our Company, Mr. Qiu is in charge of overall management, R&D and business strategy of our Company. Despite the fact that the roles of our chairman of the Board and our general manager are both performed by Mr. Qiu which constitutes a deviation from Code Provision C.2.1 of the CG Code, the Board considers that vesting the roles of both chairman of the Board and general manager all in Mr. Qiu has the benefit of ensuring consistent leadership and more effective and efficient overall strategic planning of our Company. The balance of power and authority is ensured by the operation of our Board, which comprises experienced and diverse individuals. The Board currently comprises two non-executive Directors and three independent non-executive Directors as compared to three executive Directors. The Board has designated Mr. Fung Che Wai, Anthony, an independent non-executive Director, to assume the position of the lead independent non-executive Director ("**Lead INED**") with effect from August 15, 2025. Therefore, the Board possesses a strong independent element in its composition. The Board will continue to review and monitor the practices of our Company with an aim of maintaining a higher standard of corporate governance.

Our Company is committed to enhancing its corporate governance practices used to regulate conduct and promote growth of its business and to reviewing such practices from time to time to ensure that we comply with the CG Code and align with the latest developments of our Company.

RISK MANAGEMENT AND INTERNAL CONTROL

The Board acknowledges its responsibility for the risk management and internal control systems and reviewing their effectiveness. Such systems are designed to manage rather than eliminate the risk of failure to achieve business objectives, and can only provide reasonable and not absolute assurance against material misstatement or loss.

The Board has the overall responsibility for evaluating and determining the nature and extent of the risks it is willing to take in achieving our Company's strategic objectives, and establishing and maintaining appropriate and effective risk management and internal control mechanisms.

INTERIM DIVIDEND

The Board has resolved not to declare the payment of interim dividend for the six months ended June 30, 2025 to the Shareholders (six months ended June 30, 2024: nil).

USE OF PROCEEDS FROM THE GLOBAL OFFERING

The H Shares of our Company were listed on the Main Board of the Stock Exchange on March 20, 2024. The net proceeds received from the Global Offering, after deducting the underwriting fees and commissions and expenses payable by our Company in connection with the Global Offering, amounted to approximately HK$163.3 million. As of June 30, 2025, our Company did not change its plan on the use of proceeds as stated in the Prospectus and had utilize HK$36.3 million of the proceeds from the Global Offering. Our Company intends to use the net proceeds in the same manner and proportion as set out in the section headed "Future Plans and Use of Proceeds" of the Prospectus.

EVENTS AFTER THE FINANCIAL PERIOD

On July 4, 2025, in order to effectively utilize its idle funds, the Company entered into two subscription agreements with PDB to subscribe for two wealth management products offered by PDB, the principal terms of which are set out below. The Company agreed to subscribe for wealth management products offered by PDB, amounting to RMB120 million in principal and maturing on October 9, 2025. Details of the transaction are set out in the announcement of the Company dated July 4, 2025.

The Board has designated Mr. Fung Che Wai, Anthony, an independent non-executive Director, to assume the position of the Lead INED with effect from August 15, 2025 for the purpose of adopting a high standard of corporate governance. The Lead INED will not have a separate or higher level of responsibility or liability relative to other independent non-executive Directors. He will serve as a channel of communication to enable shareholders to understand the actions taken by independent non-executive Directors ("**INEDs**") in the performance of their responsibilities, as an intermediary between Directors and shareholders and enhance the communications among the INEDs and between the INEDs and the rest of the Board. The Lead INED is not an executive position in the Company and does not have any management role in the Group. Mr. Fung Che Wai, Anthony's other positions in the Board and the relevant Board committees remain unchanged. Details of the designation are set out in the announcement of the Company dated August 15, 2025.

Save as disclosed in this announcement, we are not aware of any material subsequent events from the end of the Reporting Period to the date of this announcement.

AUDIT COMMITTEE AND REVIEW OF FINANCIAL STATEMENTS

The Group has established the Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code as set out in Appendix C1 to the Listing Rules. The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal controls system of the Group, review and approve connected transactions and to advise the Board. The Audit Committee comprises three members, namely Mr. Fung Che Wai, Anthony, Mr. Wu Zhiqiang and Dr. Ling Jianqun, with Mr. Fung Che Wai, Anthony being the chairman of the Audit Committee.

The financial information for the six months ended June 30, 2025 set out in the interim results announcement is unaudited but has been reviewed by the Audit Committee. The Audit Committee has reviewed this announcement and was satisfied that the Company's unaudited financial information contained in this interim results announcement was prepared in accordance with applicable accounting standards. The Audit Committee has considered and reviewed the accounting principles and practices adopted by the Group, and discussed matters in relation to, among others, risk management, internal control and financial reporting of the Group with management and the Company's external auditor. The Audit Committee is of the view that the interim financial results for the six months ended June 30, 2025 have complied with relevant accounting standards, rules and regulations, and have been officially and properly disclosed.

KPMG, the Company's external auditor, has carried out a review of the unaudited interim consolidated financial statements for the six months ended June 30, 2025 in accordance with Hong Kong Standard on Review Engagements 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Hong Kong Institute of Certified Public Accountants.

PUBLICATION OF INTERIM RESULTS AND INTERIM REPORT

This results announcement is published on the websites of the Stock Exchange (http://www.hkexnews.hk) and the Company (www.qyuns.net). The interim report of the Group for the six months ended June 30, 2025 containing all the relevant information required by the Listing Rules will be published on the websites of the Stock Exchange and the Company, in accordance with the Listing Rules in due course.

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

DEFINITIONS

"ankylosing spondylitis" or "AS"	a chronic progressive inflammatory disease that is primarily characterized by inflammation of the spinal joints, leading to reduced flexibility of the joints and stiffness in the spine over time
"antibody"	a protein produced in response to and counteracting a specific antigen. Antibodies combine chemically with substances which the body recognizes as alien, such as bacteria, viruses and foreign substances in the blood
"Articles of Association" or "Articles"	the articles of association of our Company adopted on June 20, 2025 which have become effective as of the same day, as amended from time to time
"ASAS20"	Assessment of Spondyloarthritis International Society 20, a widely used measurement of symptom improvement in AS patients, defined as (i) an improvement of no less than 20% from baseline (and absolute improvement from baseline of at least 1 on a 0-to-10 scale) in at least three of the following four domains: patient global assessment of disease, total back pain, function (as assessed by the Bath Ankylosing Spondylitis Functional Index) and inflammation, and (ii) an absence of deterioration from baseline (meaning a worsening of no less than 20% and absolute worsening of at least 1 on a 0-to-10 scale) in the remaining domain
"ASAS40"	Assessment of Spondyloarthritis International Society 40, defined as an improvement of no less than 40% in at least three of the four domains (same as ASAS20) with an absolute improvement of at least 2 on a 0-to-10 scale, and no worsening in the remaining domain
"associate(s)"	has the meaning ascribed to it under the Listing Rules
"atopic dermatitis" or "AD"	an immune-mediated inflammatory skin disease that causes dry, itchy and inflamed skin
"Audit Committee"	the audit committee of our Board

"Authorized Fields"	the fields where QX005N, alone or in combination with other products, is suitable for use in the diagnosis, prevention and treatment of all human diseases, for all indications, in any dosage form, in any dosage and in any packaging
"Authorized Territory"	the Greater China, including Mainland China, Hong Kong, Macau and Taiwan
"autoimmune"	with respect to any disorder or disease, an abnormal immune response of the body against substances and tissues normally present in the body
"biologics"	drug products derived from a variety of natural sources-human, animal, or microorganism-that may be produced by biotechnology methods and other cutting-edge technologies (in contrast to small-molecule drugs, which are chemically synthesized). Biologics can be composed of sugars, proteins or nucleic acids or complex combinations of these substances, or may be living entities, such as cells and tissues
"biosimilar"	a follow-on version of innovator biopharmaceuticals which are separately developed after patents protecting the innovator biopharmaceuticals have expired and have similar quality, safety and efficacy as the innovator biopharmaceuticals
"BLA"	the Biologics License Application
"Board" or "Board of Directors"	the board of Directors
"Caldera"	Caldera Therapeutics, Inc., a Delaware corporation with a business address at 300 Technology Square, 8th Floor, Cambridge, MA 02139, U.S.A.
"CDMO"	a contract development and manufacturing organization, which provides support to the pharmaceutical industry by providing development and manufacturing services outsourced on a contract basis
"cell line"	a population of cells that descend from a single cell and contain the same genetic makeup, and can be propagated repeatedly
"Cellularforce"	Jiangsu Cellularforce Biopharma Co., Ltd. (江蘇賽孚士生物技術有限公司), a company established in the PRC with limited liability on August 2, 2018 and an indirect non-wholly owned subsidiary of our Company which is owned as to 66% by Saifu Juli and 34% by Taizhou Huacheng

"CG Code" or "Corporate Governance Code"	the Corporate Governance Code contained in Appendix C1 to the Listing Rules, as amended, supplemented or otherwise modified from time to time
"China" or "PRC"	The People's Republic of China, but for the purpose of this announcement and for geographical reference only and except where the context requires otherwise, references in this announcement to "China" and the "PRC" do not apply to Hong Kong, Macau and Taiwan
"chronic obstructive pulmonary disease" or "COPD"	a chronic inflammatory lung disease that causes obstructed airflow from the lungs, symptoms including breathing difficulty, cough and mucus production
"chronic rhinosinusitis with nasal polyps" or "CRSwNP"	a subgroup of chronic rhinosinusitis characterized by the presence of fleshy swellings (nasal polyps) that develop in the lining of the nose and paranasal sinuses
"chronic spontaneous urticaria" or "CSU"	the occurrence of urticaria for six weeks or longer with identifiable specific triggers
"clinical trial"	a research study for validating or finding the therapeutic effects and side effects of test drugs in order to determine the therapeutic value and safety of such drugs
"Code Provision(s)"	the principles and code provisions set out in the CG Code
"Company"	Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥股份有限公司) (formerly known as Qyuns Therapeutics Co., Ltd. (江蘇荃信生物醫藥有限公司)), a company established in the PRC with limited liability on June 16, 2015 which was converted into a joint stock company with limited liability on September 30, 2021
"Company Law" or "PRC Company Law"	the Company Law of the PRC (中華人民共和國公司法), as amended, supplemented or otherwise modified from time to time
"connected person(s)"	has the meaning ascribed to it under the Listing Rules
"connected transaction(s)"	has the meaning ascribed to it under the Listing Rules

"Controlling Shareholder(s)"	has the meaning ascribed to it under the Listing Rules and, unless the context requires otherwise, refers to Mr. Qiu, Mr. Yu Guo'an, Hangzhou Quanyi, Shanghai Quanyou and Xinfu Tongxin; and a Controlling Shareholder shall mean each or any of them
"Cooperation Agreement"	the Cooperation Agreement dated July 19, 2024 entered into by the Company and Zhongmei Huadong for joint development and commercialization of the QX005N
"Core Product(s)"	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purpose of this announcement, our Core Products refers to QX002N and QX005N
"CRO"	a contract research organization, which provides support to the pharmaceutical industry by providing research and development services outsourced on a contract basis
"Crohn's disease" or "CD"	a chronic, incurable inflammatory bowel disease that affects the lining of the digestive tract and can sometimes cause life-threatening complications. CD symptoms can include abdominal pain, diarrhea, weight loss, anemia and fatigue
"CTN"	Clinical Trial Notification
"cytokine"	proteins secreted by cells in both innate and adaptive immune responses, which can regulate diverse functions in the immune response
"Director(s)"	the director(s) of our Company
"EIT Law"	the PRC Enterprise Income Tax Law (中華人民共和國企業所得税法), as enacted by the NPC on March 16, 2007 and effective on January 1, 2008, as amended, supplemented or otherwise modified from time to time
"Employee Share Incentive Scheme"	the restricted share scheme approved and adopted by our Company on September 15, 2022
"endpoint"	with respect to a clinical study or trial, the outcome that is measured
"Global Offering"	the global offering of 12,046,400 H Shares as described in the Prospectus
"Group", "our Group", "the Group", "we," "us" or "our"	our Company and all of our subsidiaries (or our Company and anyone or more of its subsidiaries, as the context may require)
"H Share(s)"	shares of our Company for which an application has been made for listing and permission to trade on the Stock Exchange

"Hangzhou Quanyi"	Hangzhou Quanyi Investment Management Partnership (General Partnership)* (杭州荃毅投資管理合夥企業(普通合夥)), a general partnership established in the PRC on May 15, 2015 and one of our Controlling Shareholders, which is owned as to 50% by Mr. Qiu and 50% by Mr. Yu Guo'an, both as its general partners acting in concert
"Hansoh Pharma"	Hansoh Pharmaceutical Group Company Limited (翰森製藥集團有限公司), a pharmaceutical company whose shares are listed on the Stock Exchange (stock code: 3692)
"Hansoh (Shanghai)"	Hansoh (Shanghai) Healthtech Co., Ltd.* (翰森(上海)健康科技有限公司), a wholly-owned subsidiary of Hansoh Pharma
"Hong Kong" or "HK"	the Hong Kong Special Administrative Region of the PRC
"Hong Kong dollar(s)" or "HK$"	Hong Kong dollar(s), the lawful currency of Hong Kong
"Huadong Medicine"	Huadong Medicine Co., Ltd.* (華東醫藥股份有限公司), a pharmaceutical company whose shares are listed on the Shenzhen Stock Exchange (stock code: 000963)
"IgG"	human immunoglobulin G, the most common antibody type found in blood circulation that plays an important role in antibody-based immunity against invading pathogens
"IL"	interleukin, a type of cytokine-signaling molecule in the immune system to provoke an immune response in the body of a human and other animals
"immunoglobulin" or "Ig"	also known as antibody, a glycoprotein molecule produced by plasma cell (white blood cell)
"Independent Third Party(ies)"	individuals or company(ies), who or which, to the best of our Directors' knowledge, information and belief, having made all reasonable enquiries, is not a connected person of our Company within the meaning of the Listing Rules
"inhibitor"	a substance added or applied to another substance to slow down a reaction or to prevent an unwanted chemical change
"Joincare"	Joincare Pharmaceutical Group Industry Co., Ltd. (健康元藥業集團股份有限公司), a company listed on the Shanghai Stock Exchange (stock code: 600380), our licensing partner for QX008N
"Listing"	the listing of our H Shares on the Main Board

"Listing Date"	March 20, 2024, on which dealings in our H Shares first commence on the Main Board
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented or otherwise modified from time to time
"Macau"	the Special Administrative Region of Macau of the PRC
"MAH"	the marketing authorization holder
"Main Board"	the stock exchange (excluding the option market) operated by the Stock Exchange which is independent from and operated in parallel with the Growth Enterprise Market of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules, as amended, supplemented or otherwise modified from time to time
"monoclonal antibody" or "mAb"	antibody generated by identical immune cells that are all clones of the same parent cell
"Mr. Qiu"	Mr. Qiu Jiwan (裘霽宛), our founder, executive Director, chairman of our Board, our general manager, and one of our Controlling Shareholders
"pharmacology"	a branch of medicine and pharmaceutical sciences which is concerned with the study of drug or medication action, where a drug can be broadly or narrowly defined as any man-made, natural or endogenous molecule which exerts a biochemical or physiological effect on the cell, tissue, organ or organism
"Phase I clinical trial"	study in which a drug is introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion and, if possible, an early indication of its effectiveness. Phase I clinical trial can be further divided into the Phase Ia clinical trial, which is often a single ascending dose study, and the Phase Ib clinical trial, which is often a multiple ascending dose study
"Phase II clinical trial"	study in which a drug is administered to a limited patient population to identify possible adverse effects and safety risks, preliminarily evaluate the efficacy of the product for specific targeted diseases and determine dosage tolerance and optimal dosage

"Phase III clinical trial"	study in which a drug is administered to an expanded patient population generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval and to provide adequate information for the labeling of the product
"Prospectus"	the prospectus issued by our Company on March 12, 2024 in relation to our Global Offering and Listing
"prurigo nodularis" or "PN"	a chronic skin disorder characterized by the presence of hard and extremely itchy bumps known as nodules, which tend to be found in easy-to-scratch areas, such as the arms, legs, the upper back and abdomen
"psoriasis" or "Ps"	a skin disease associated with dysregulation of the immune systems that causes a rash with itchy and scaly patches, most commonly on the knees, elbows, trunk and scalp
"receptor"	a region of tissue, or a molecule in a cell membrane, which responds specifically to a particular signal, that is any of a neurotransmitter, hormone, antigen or other substance
"Remuneration and Appraisal Committee"	the remuneration and appraisal committee of our Board
"Renminbi" or "RMB"	the lawful currency of the PRC
"Reporting Period"	the six months ended June 30, 2025
"Saifu Juli"	Taizhou Saifu Juli Biomedical Co., Ltd.* (泰州市賽孚聚力生物醫藥有限公司), a company established in the PRC with limited liability on July 6, 2018 and a direct wholly owned subsidiary of our Company
"Shanghai Quanyou"	Shanghai Quanyou Fanyue Investment Management Partnership (Limited Partnership)* (上海荃友凡悦投資管理合夥企業(有限合夥)), a limited partnership established in the PRC on November 2, 2015 and one of our Controlling Shareholders, which is owned as to approximately 45.71% by Mr. Qiu as its general partner, 8.57% by Ms. Xu Qiu (許秋), the spouse of Mr. Qiu, as one of its limited partners, and 45.71% by three Independent Third Parties as its other limited partners
"Share(s)"	ordinary share(s) with par value RMB1.00 each in the share capital of the Company
"Shareholder(s)"	holder(s) of our Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited, a wholly owned subsidiary of Hong Kong Exchange and Clearing Limited

"subsidiary(ies)"	has the meaning ascribed to it under the Listing Rules
"Supervisor(s)"	the supervisor(s) of our Company
"TNF"	tumor necrosis factor, a group of cell signaling proteins (cytokines) that regulate immune cells and mediate the inflammatory responses
"TNF- α"	a prominent member of the TNF family and one of the cytokines that make up the acute phase reaction, a series of physiological process occurring soon after the onset of inflammatory processes
"TSLP"	thymic stromal lymphopoietin, a protein belonging to the cytokine family, which plays an important role in the maturation of T cell populations through activation of antigen presenting cells (APCs)
"Unlisted Share(s)"	ordinary Share(s) issued by our Company with a nominal value of RMB1.00 each which is/are not listed on any stock exchange
"urticaria"	a type of skin disease characterized by itchy swelling on the skin surface
"U.S." or "United States"	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"U.S. dollar(s)" or "US$"	United States dollar(s), the lawful currency of the United States
"Xinfu Quanxin"	Taizhou Xinfu Quanxin Enterprise Management Partnership (Limited Partnership)* (泰州信孚全心企業管理合夥企業(有限合夥)), a limited partnership established in the PRC on February 27, 2023, which is owned as to approximately 0.56% by Mr. Wu Yiliang, our executive Director and executive deputy general manager of Cellularforce as its general partner and approximately 99.44% by 27 employees of our Group as its limited partners, and is one of our employee share incentive platforms
"Xinfu Tongxin"	Taizhou Xinfu Tongxin Enterprise Management Partnership (Limited Partnership)* (泰州信孚同心企業管理合夥企業(有限合夥)), a limited partnership established in the PRC on August 19, 2021, which is owned as to approximately 9.36% by Mr. Qiu as its general partner, approximately 11.38% by Xinfu Quanxin as one of its limited partners and approximately 79.26% by 35 employees of our Group as its limited partners, and is one of our employee share incentive platforms and one of our Controlling Shareholders
"Zhongmei Huadong"	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.* (杭州中美華東製藥有限公司), a company established in the PRC with limited liability on December 31, 1992 and one of our Pre-IPO Investors

ACRONYMS

"CDE"	Center for Drug Evaluation (國家藥品監督管理局藥品審評中心), a division of the NMPA responsible for acceptance and technical review of applications for drug clinical trials and drug marketing authorization
"cGMP"	current good manufacturing practice, regulations and procedures that provide for proper design, monitoring, and control of manufacturing processes and facilities
"CMC"	the chemistry, manufacturing and controls processes in the development, licensure, manufacturing and ongoing marketing of pharmaceutical products
"FDA"	the United States Food and Drug Administration
"FPI"	First Patient In
"IASB"	International Accounting Standards Board
"IFRS"	the International Financial Reporting Standards, which as collective term includes all applicable individual International Financial Reporting Standards, International Accounting Standards and Interpretations issued by the IASB
"IND"	Investigational New Drug
"NMPA"	the National Medical Products Administration of the PRC (國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局)
"PDB"	Shanghai Pudong Development Bank Co., Ltd. (上海浦東發展銀行股份有限公司)

By order of the Board
Qyuns Therapeutics Co., Ltd.
Mr. Qiu Jiwan
Chairman of the Board and Executive Director

Hong Kong, August 15, 2025

As at the date of this announcement, the Board comprises Mr. Qiu Jiwan as chairman and executive Director, Mr. Wu Yiliang and Mr. Lin Weidong as executive Directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive Directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive Directors.

* *For identification purposes only*